SYM FINANCIAL Corp grew its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 109.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,525 shares of the healthcare product maker's stock after buying an additional 3,930 shares during the quarter. SYM FINANCIAL Corp's holdings in Abbott Laboratories were worth $998,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of the company. Redwood Park Advisors LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at $25,000. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the first quarter worth about $27,000. WealthTrak Capital Management LLC bought a new stake in Abbott Laboratories during the 4th quarter worth about $28,000. Abound Financial LLC bought a new position in shares of Abbott Laboratories in the 1st quarter valued at about $28,000. Finally, Wormser Freres Gestion acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $32,000. Institutional investors own 75.18% of the company's stock.
Abbott Laboratories Stock Down 0.1%
Shares of ABT stock traded down $0.16 during trading on Thursday, reaching $125.67. The company's stock had a trading volume of 4,707,972 shares, compared to its average volume of 6,987,350. The company has a market cap of $218.65 billion, a price-to-earnings ratio of 15.75, a price-to-earnings-growth ratio of 2.38 and a beta of 0.73. Abbott Laboratories has a one year low of $99.92 and a one year high of $141.23. The business has a fifty day moving average price of $132.71 and a 200-day moving average price of $129.70. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.26.
Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.83% and a net margin of 32.43%. The company had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same quarter last year, the company earned $1.14 EPS. Abbott Laboratories's revenue for the quarter was up 7.4% compared to the same quarter last year. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.
Abbott Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.88%. Abbott Laboratories's payout ratio is 29.57%.
Wall Street Analyst Weigh In
A number of analysts have commented on ABT shares. BTIG Research lowered their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. Leerink Partners started coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price on the stock. Raymond James Financial decreased their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Barclays lifted their price objective on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research note on Thursday, April 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 target price (up previously from $133.00) on shares of Abbott Laboratories in a research note on Thursday, April 17th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $144.47.
Read Our Latest Stock Report on ABT
Insider Transactions at Abbott Laboratories
In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director owned 34,058 shares of the company's stock, valued at $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.46% of the company's stock.
Abbott Laboratories Company Profile
(
Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Read More

Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.